ESTRO 2024 - Abstract Book

S1199

Clinical - Head & neck

ESTRO 2024

Figure 1: A representative case illustrating 40BED and 50BED isodose colour wash. The biologically effective dose (BED) was determined for both a total physical dose of 36Gy and 44Gy delivered over 30 fractions using an α/β ratio = 10 resulting in 40Gy BED10 and 50Gy BED10, respectively.

Conclusion:

We have shown in our previously published work that patients with a diagnosis of SCCUP head and neck may be safely treated with INO RT. 3 We now have extended follow-up for this cohort. No contralateral neck relapses or primaries emerged in patients treated with INO radiotherapy after prolonged follow-up. This may be partly due to the potential primary sites receiving an incidental mean dose of RT between 40-55Gy.

Keywords: head and neck, unknown primary, radiotherapy

References:

1. Cabrera Rodriguez J, Cacicedo J, Giralt J, Garcia Miragall E, Lloret M, Arias F, et al. GEORCC recommendations on target volumes in radiotherapy for Head Neck Cancer of Unkown Primary. Crit Rev Oncol Hematol. 2018 Oct;130:51 9.

2. Cerezo L, Raboso E, Ballesteros AI. Unknown primary cancer of the head and neck: a multidisciplinary approach. Clin Transl Oncol. 2011 Feb;13(2):88-97.

3. Poon WY, Thomson M, McLoone P, Wilson C, Crosbie R, Schipani S, et al. Comparative cohort study of volumetric modulated arc therapy for squamous cell cancer of unknown primary in the head and neck – Involved neck only versus mucosal irradiation. Clin Otolaryngol. 2020 Nov;45(6):847-852. 4. Hardman J C, Williamson A, Hulse K, Milinis K, Dobbs S, Khosla S, Hogan C, Constable J. INTEGRATE (The UK ENT Trainee Research Network). Survival outcomes in head and neck squamous cell carcinoma of unknown primary (HNSCCUP): National audit of current practice in the United Kingdom. Presented at ENT UK HNSCCUP Consensus Day. SAGE, Gateshead, United Kingdom.15 Nov 2021